Pharma News

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

11 October 2021

BRUKINSA approved for treatment of Patients with Mantle Cell Lymphoma

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

6 October 2021

Manganese makes its mark in drug synthesis

Rice chemist Julian West and graduate student Yen-Chu Lu found that an Earth-abundant salt of manganese further simplifies the process of synthesizing fluoroketones, precursor molecules for drug design and manufacture.

The complex method required catalysts of expensive silver until the West lab figured out how to replace it with a cerium-based compound. That in turn led the researchers to eye manganese as a next-level catalyst.

6 October 2021

Cancer chemotherapy drug reverses Alzheimer symptoms in mice

A drug commonly used to treat cancer can restore memory and cognitive function in mice that display symptoms of Alzheimer’s disease, new UBC research has found.

2 October 2021

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficiency of IDS and manifests in different forms.

2 October 2021

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

2 October 2021

NPPA condemns false statements regarding its connivance in any malpractices adopted by Pharmaceutical Companies

National Pharmaceutical Pricing Authority is a regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India and is committed to ensure affordability and accessibility of medicines by fixing the ceiling price for scheduled formulations and monitoring the prices of non-scheduled formulations.

1 October 2021

Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.

1 October 2021

BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE announced that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients.

1 October 2021

Gujarat State Pharmacy Council to offer financial assistance to family of pharmacist who died in Corona pandemic

Gujarat State Pharmacy Council (GSPC) had organised celebration of World Pharmacist Day on 25th Sept 2021 in which more than 300 pharmacists from the pharmacy sector of the state of Gujarat were present. In this event GSPC announced financial assistance to the family of a Gujarat pharmacist who died while on duty in Corona pandemic.

28 September 2021

DBT Institute to help Vietnamese company develop COVID vaccine

After helping several Indian companies in the development of vaccines for COVID-19 including clinical trials, the Department of Biotechnology (DBT)’s Translational Health Science and Technology Institute (THSTI) has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company which is in the process of developing a vaccine for the disease.

Search

BRUKINSA approved for treatment of Patients with Mantle Cell Lymphoma

RECOMMENDED POSTS

Subscribe with us

Jobs by Category